Banque Cantonale Vaudoise Raises Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Banque Cantonale Vaudoise increased its position in Moderna, Inc. (NASDAQ:MRNA) by 4.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,130 shares of the company’s stock after acquiring an additional 1,245 shares during the period. Banque Cantonale Vaudoise’s holdings in Moderna were worth $3,464,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Ogorek Anthony Joseph NY ADV purchased a new position in Moderna in the 4th quarter worth $27,000. Cedar Wealth Management LLC raised its stake in shares of Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares during the last quarter. Westside Investment Management Inc. purchased a new position in shares of Moderna during the 1st quarter valued at about $32,000. Family Firm Inc. purchased a new position in shares of Moderna during the 2nd quarter valued at about $33,000. Finally, Rise Advisors LLC raised its stake in shares of Moderna by 953.3% during the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after buying an additional 286 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO James M. Mock sold 689 shares of the business’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the transaction, the chief financial officer now owns 7,269 shares in the company, valued at $859,486.56. The disclosure for this sale can be found here. Insiders have sold a total of 330,736 shares of company stock worth $46,330,112 in the last ninety days. Insiders own 15.70% of the company’s stock.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of recent research reports. The Goldman Sachs Group reduced their price objective on Moderna from $204.00 to $178.00 and set a “buy” rating for the company in a research note on Friday, August 2nd. Evercore ISI reiterated an “in-line” rating and set a $120.00 price objective on shares of Moderna in a research note on Thursday, June 27th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and reduced their price objective for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. Canaccord Genuity Group lifted their price target on Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research note on Friday, May 3rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Thursday, August 1st. Ten analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $123.79.

Moderna Price Performance

MRNA stock traded down $0.19 during trading on Friday, hitting $77.40. The stock had a trading volume of 3,591,705 shares, compared to its average volume of 4,083,584. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.91. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $170.47. The stock has a market capitalization of $29.66 billion, a P/E ratio of -4.94 and a beta of 1.67. The company’s 50-day moving average price is $104.62 and its two-hundred day moving average price is $112.80.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. Moderna’s revenue was down 29.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($3.62) EPS. As a group, research analysts predict that Moderna, Inc. will post -7.46 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.